Prosecution Insights
Last updated: May 29, 2026
Application No. 18/336,792

GLYCOPROTEIN HORMONE RECEPTOR MUTATIONS

Final Rejection §DOUBLEPATENT
Filed
Jun 16, 2023
Priority
Jun 11, 2014 — GB 1410409.5 +2 more
Examiner
PAK, MICHAEL D
Art Unit
1674
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Rsr Limited
OA Round
2 (Final)
58%
Grant Probability
Moderate
3-4
OA Rounds
9m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
406 granted / 697 resolved
-1.8% vs TC avg
Strong +31% interview lift
Without
With
+30.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
15 currently pending
Career history
727
Total Applications
across all art units

Statute-Specific Performance

§101
3.1%
-36.9% vs TC avg
§103
31.3%
-8.7% vs TC avg
§102
23.2%
-16.8% vs TC avg
§112
28.5%
-11.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 697 resolved cases

Office Action

§DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Claims filed October 23, 2025 is entered. Claims 1-20 are pending. Claims 2-6, 11-12, 16-18 are withdrawn. Claims 1, 7-10, 13-15, 19-20 are examined. 3. Declaration under 37 CFR 1.132 is sufficient to overcome the 35 USc 112 rejections. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 7-10, 13-15 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-8 of U.S. Patent No. 11,732,026. Although the claims at issue are not identical, they are not patentably distinct from each other. Claims 1-8 of U.S. Patent No. 11,732,026 encompass identical claim limitations or anticipate the pending claims 1, 7-10, 13-15. No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL D PAK whose telephone number is (571)272-0879. The examiner can normally be reached on flexible. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joanne Hama, can be reached on 571-272-08572911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL D PAK/Primary Examiner, Art Unit 1674
Read full office action

Prosecution Timeline

Jun 16, 2023
Application Filed
Mar 04, 2024
Response after Non-Final Action
Apr 24, 2025
Non-Final Rejection mailed — §DOUBLEPATENT
Oct 23, 2025
Response after Non-Final Action
Oct 23, 2025
Response Filed
Jan 28, 2026
Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12638457
RAN PROTEINS AS BIOMARKERS IN CAG/CTG EXPANSION DISORDERS
4y 1m to grant Granted May 26, 2026
Patent 12629418
COMBINATION THERAPY USING INHIBITORS OF HUMAN GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15) AND IMMUNE CHECKPOINT BLOCKERS
3y 8m to grant Granted May 19, 2026
Patent 12624113
ANTI-HUMAN CCR1 MONOCLONAL ANTIBODY
2y 8m to grant Granted May 12, 2026
Patent 12606603
IL-13 RECEPTOR ALPHA 2 TARGETED, ZETAKINE DIRECTED T CELL IMMUNOTHERAPY
5y 7m to grant Granted Apr 21, 2026
Patent 12605405
NOVEL METHODS FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS
5y 2m to grant Granted Apr 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
58%
Grant Probability
89%
With Interview (+30.6%)
3y 8m (~9m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 697 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month